Compare AbCellera Biologics Inc (ABCL) vs VF Corp (VFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs VF Corp — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while VF Corp trades at $16 (market cap $6.45B). The key difference: VF Corp is far larger — about 2.7× AbCellera Biologics Inc's market cap, and VF Corp pays a 2.19% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | VFC | |
|---|---|---|
Market Cap | $2.35B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $21.55 |
52-Week Low | $2.78 | $11.66 |
Enterprise Value | $1.99B | $10.60B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VFC trades at $16.45, up 0.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings showed a Q1 2026 miss after two prior beats, while revenue declined to $9.50B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M. Analyst consensus is mixed with a $20.00 price target, and news highlights focus on turnaround progress and debt reduction.
VFC's outlook hinges on executing its brand turnaround, particularly at Vans, with guided revenue growth for 2027 offering potential upside. Risks include weak consumer confidence and high leverage, though deleveraging efforts are underway. The stock presents a value opportunity with a low P/S of 0.68, but investors face near-term volatility from earnings uncertainty and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
